Neuroblastoma in the UK is seeing the development of potential new therapies

UK's national research charity Neuroblastoma UK has received news that new treatments for children with neuroblastoma are entering clinical trials.
the drug has passed adult safety trials and indirectly targets N-Myc, a gene that appears in an invasive form of neuroblastoma.
the treatment, which blocks N-Myc activity by shutting down gene production, is expected to conduct a clinical trial in children with high-risk neuroblastoma by the end of 2020.In mice, the drug slowed down and stabilized tumor growth, and mice receiving the drug survived longer after treatment than untreated mice.
when used in mice in combination with chemotherapy, these drugs shrink tumors to the extent that they can almost be eliminated.
study of the therapy, fadraciclib, was led by scientists at the Institute of Cancer Research and published earlier this week in the Journal of Clinical Research.Tony Heddon, chairman of Neuroblastoma UK, said: "We welcome the news that new treatments are likely to be used in clinical trials and will reach more young cancer patients.
less than 50 percent of children with high-risk neuroblastoma survive five years or more after diagnosis. For children who do survive, the drugs used to save them can cause long-term damage.
”“ There is a real need to provide our children with less toxic and more effective treatments. This important development offers real hope to families suffering from this life-threatening cancer. He added. （cyy123.com）